LZ-167
Oncology (specific indications not disclosed)
Pre-clinicalActive
Key Facts
About KeyZell
KeyZell Biotech is a private, pre-clinical stage biopharmaceutical company pioneering a novel oncology therapeutic, LZ-167, supported by an AI-driven precision medicine platform. Founded in 2018 and headquartered in Seville, Spain, the company aims to initiate international clinical trials in 2024, targeting a significant unmet need in cancer care with a therapy designed for efficacy and reduced side effects. Backed by leadership with business and scientific expertise and recognized through awards like the Santander X Global Challenge, KeyZell is positioning itself as a potential disruptor in the global oncology market.
View full company profile